BDX: Becton, Dickinson and Company - Summary | Jitta

Becton, Dickinson and Company

NYSE:BDX

Price
$253.48
Loss Chance
44.4%
5.25JITTA SCORE
30.35%Over Jitta Line
Jitta Ranking
56 / 1,042
963 / 4,597
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (38)
Recent Business Performance (58)
Financial Strength (72)
Return to Shareholders (48)
Competitive Advantage (54)
Jitta Signs
Dividend PayoutIncreasing Every Year
Interest Coverage RatioVery Good
Revenue and EarningEarning decline from 2017-2020
Operating MarginDeclined
Recent Business PerformanceEarning decline 16.74% in the last year
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
5.25
30.35%
2.24
353.92%
Health Care Equipment
7.22
80.79%
3.25
14.25%
7.64
361.01%
COMPANY DESCRIPTION
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company’s BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company’s BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.